Table 2.
Economic features of the included studies
| Feature | N | % |
|---|---|---|
|
Type of economic evaluation |
|
|
| CEA |
21 |
70 |
| CUA |
5 |
17 |
| CBA |
4 |
13 |
|
Study design |
|
|
| RCT |
8 |
27 |
| Quasi-experimental |
3 |
10 |
| Modelling |
6 |
20 |
| Observational (prospective, retrospective etc.) |
13 |
43 |
|
Perspective evaluated |
|
|
| Societal |
0 |
0 |
| Government |
3 |
10 |
| Healthcare system/Healthcare provider |
23 |
77 |
| Third party |
2 |
7 |
| Patients |
1 |
3 |
| Mixed |
1 |
3 |
|
Type of sensitivity analysis |
|
|
| One-way analysis |
5 |
17 |
| Multi-way analysis |
1 |
3 |
| Univariate/multivariate regression |
1 |
3 |
| Probabilistic analysis |
1 |
3 |
| Not performed |
22 |
73 |
|
Time horizon |
|
|
| <= 1 year |
8 |
27 |
| 1-10 years |
5 |
17 |
| Over 10 years |
5 |
17 |
| Not specified |
12 |
40 |
|
Type of outcome |
|
|
| QALY/DALY |
5 |
17 |
| Intermediate (physiological, functional, etc.) |
21 |
70 |
| Monetary |
4 |
13 |
|
Level of care and intervention type |
|
|
| Primary prevention |
2 |
7 |
| Curative (Surgical/Medical procedure) |
10 |
33 |
| Curative (Pharmaceuticals) |
7 |
23 |
| Diagnostic/screening (secondary prevention) |
10 |
33 |
| Mode of delivery of care |
1 |
3 |
|
Type of data used |
|
|
| Primary data |
22 |
73 |
| Secondary data |
4 |
13 |
| Mixed |
4 |
13 |
|
Type of costs included |
|
|
| Direct medical costs |
30 |
100 |
| Direct non-medical costs |
4 |
13 |
| Indirect costs (Productivity loss) | 0 | 0 |